Shuttle Pharmaceuticals (NASDAQ:SHPH) Trading Up 16.8% – Here’s Why

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) shot up 16.8% on Monday . The company traded as high as $1.77 and last traded at $1.67. 263,739 shares were traded during mid-day trading, a decline of 50% from the average session volume of 530,633 shares. The stock had previously closed at $1.43.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SHPH shares. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a research report on Tuesday, November 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 16.8%

The company has a market capitalization of $2.67 million, a price-to-earnings ratio of -0.14 and a beta of -0.87. The stock’s 50 day moving average price is $3.06 and its 200 day moving average price is $3.60.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .